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Abstract
Background: Melanoma is the most aggressive and lethal form of skin cancer. Because of the increasing incidence and high
lethality of melanoma, animal models for continuously observing melanoma formation and progression as well as for
testing pharmacological agents are needed.
Methodology and Principal Findings: Using the combinatorial Gal4 –UAS system, we have developed a zebrafish
transgenic line that expresses oncogenic HRAS under the kita promoter. Already at 3 days transgenic kita-GFP-RAS larvae
show a hyper-pigmentation phenotype as earliest evidence of abnormal melanocyte growth. By 2–4 weeks, masses of
transformed melanocytes form in the tail stalk of the majority of kita-GFP-RAS transgenic fish. The adult tumors evident
between 1–3 months of age faithfully reproduce the immunological, histological and molecular phenotypes of human
melanoma, but on a condensed time-line. Furthermore, they show transplantability, dependence on mitfa expression and
do not require additional mutations in tumor suppressors. In contrast to kita expressing melanocyte progenitors that
efficiently develop melanoma, mitfa expressing progenitors in a second Gal4-driver line were 4 times less efficient in
developing melanoma during the three months observation period.
Conclusions and Significance: This indicates that zebrafish kita promoter is a powerful tool for driving oncogene
expression in the right cells and at the right level to induce early onset melanoma in the presence of tumor suppressors.
Thus our zebrafish model provides a link between kita expressing melanocyte progenitors and melanoma and offers the
advantage of a larval phenotype suitable for large scale drug and genetic modifier screens.
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Introduction
Melanoma development has classically been described as a
stepwise process in which mature melanocytes acquire increasing
number of mutations in oncogenes or tumor suppressor genes
leading to uncontrolled proliferation, acquisition of invasive
properties and metastatic potential [1]. However the progression
from benign nevi, radial growth, vertical growth and metastatic
melanomas is not a universal feature of all melanomas, with more
than 50% of the tumors originating from normal skin, rather than
from dysplastic nevi [2]. This data suggest that although
melanoma appears to be due to the transformation of mature
melanocytes, it may derive from melanocytic progenitor or stem
cells that upon transformation become able to initiate and
maintain cancer development.
The identification of melanoma initiating cells (MICs) is of
paramount importance to devising methods for early detection
and eradication of the disease. To this end, the most valuable tools
are in vivo models of melanoma that can be used to study the cell
of origin of the disease, the mechanisms of transformation and the
markers that distinguish the progressive changes in tumor cells and
monitor/target them at early stages.
A number of genetic mouse models have been engineered to
express oncogenes in melanocytes [3]. Regardless of the oncogene
used, the presence of inactivating mutations of tumor suppressors or
other genetic modifiers, these transgenicmodels use the promoter of
the tyrosinase (tyr) gene, which is expressed in melanocytes, but not in
their progenitors, thus practically selecting the population of cells to
transform. Furthermore, the large size and inaccessibility of mouse
embryos developing in utero make it difficult to address early
developmental processes of melanocyte transformation.
Zebrafish embryos are small in size, develop outside their mother
and are nearly transparent allowing for melanocytes to be followed
during all stages of their development. This has been exploited for
establishing melanoma models in zebrafish, which coupled with the
ease of administration of chemicals through the water make them
ideal for drug screening [4]. All the models developed so far use the
promoterofthe mitfa gene [5,6,7,8]to driveoncogene expression.In
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using the Xmrk oncogene [7], melanoma develops only in the
presence of coadjuvating mutations in p53 [5,8] or if they do arise
spontaneously then again take several months to materialize and
then only infrequently [6].
Here we report on a zebrafish model of melanoma that
expresses oncogenic HRAS under the kita promoter and develops
melanoma by 1–3 months of age, without the need of coadjuvating
mutations in tumor suppressors
Results
Expression of oncogenic HRAS driven by kita promoter/
enhancer sequences induces hyperproliferation of
embryonic melanocytes
In order to generate a flexible zebrafish model of melanoma we
took advantage of the UAS-Gal4 binary system, which has been
extensively used in Drosophila and lately developed for the
zebrafish [9,10,11,12,13].
We crossed fish from Et(kita:GalTA4,UAS:mCherry)hzm1 line [13]
with fish from the Tg(UAS:eGFP-H-RAS_GV12)io6 line [14] and
observed that larvae expressing oncogenic HRAS in a pattern
driven by kita regulatory sequences show an altered pigment
pattern and increased pigmentation already starting from 3dpf
(figure 1a, b). To simplify nomenclature, we will refer to larvae/
adult from this cross as kita-GFP-RAS zebrafish and to controls,
which derive from a cross between the Et(kita:GalTA4,UAS:mCher-
ry)hzm1 and the Tg(UAS:eGFP) (a gift of Masa Tada, UCL, see
material and methods) lines, as kita-GFP zebrafish.
When kita-GFP-RASV12 embryos were analyzed for transgene
activation, GFP fluorescence was observed in melanocytes
throughout the embryo indicating the faithful cell type specific
expression of the oncogene but also the possibility to identify
transgenic cells in vivo. Individual melanocytes in the hyperpig-
mented larvae failed to localize along the horizontal stripes where
they normally reside (figure 1b) and were significantly larger than
in controls at 3 dpf (figure 1a’, b’).
In order to evaluate if the number was increased we counted
melanocytes present in a region of interest (ROI) encompassing
the dorsal pigment stripe between the eyes and the base of the
head (outlined in figure 1c) and in the dorsal body stripe (figure 1f,
g) in the presence of constant light for 3 days as this causes
melanocyte contraction and facilitates counting [15]. Statistical
analysis revealed that kita-GFP-RASV12 larvae have double the
number of melanocytes (56.8617.9 versus 25.662.8, n=10)
compared to control larvae (figure 1e, h). This suggests that the
expression of the HRAS oncogene promotes growth and
maintains melanocytes in a proliferative state, whereas normally
Figure 1. Expression of oncogenic HRAS driven by kita promoter induces hyperpigmentation in larvae. a) A 3dpf wild-type zebrafish; b)
a kita-GFP-RAS hyperpigmented transgenic with displaced melanocytes (red arrows). A’-b’) size and shape of representative head melanocytes in
control (a’) and kita-GFP-RAS embryos (b’) c–e) Dorsal views of the head of control (c) and kita-GPF-RAS larvae (d). The red outline in (c) indicates the
ROI where counts were made. e) Quantification of the number of melanocytes (mean6SD) (mean6SD, ***p,0.001) as indicated. f–h) Dorsal views of
the lower body of control (f) and kita-GPF-RAS larvae (g). h) Quantification of the number of melanocytes (mean6SD, ***p,0.001) as indicated. i–k)
GFP marked melanocytes (green) and BrdU immunostaining (red) in kita-GFP (i) and kita-GFP-RAS (j) 4dpf zebrafish. Calibration bar: 20 mm. k)
Percentage of BrdU+ melanocytes in control (GFP) and melanoma line (Ras) at 4dpf (mean6SD, n=5). l–n) Dorsal views of heads of kita-GFP-Ras
larvae raised in DMSO (l), in U0126 (m) or in PD98059 (n) in the presence of epinephrine. o) WB analysis performed 3dpf GFP (control larvae) and RAS
(kita-GFP-RAS larvae) revealed an activation of P-ERK. p–q) Treatment with UO126 (UO) or PD98059 (PD) caused a reduction of P-ERK. Calibration bars:
50 mm for a, b, c–f, l–n; 20 mm for i–j.
doi:10.1371/journal.pone.0015170.g001
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label melanocytes that are still proliferating at 3-4 dpf. Almost all
melanocytes were BrdU labeled in kita-GFP-RAS larvae following
12 hrs exposure to BrdU at 3-4 dpf (figure 1j, k), whereas very few
(less that 5% of all melanocytes) were BrdU labelled in kita-GFP
larvae (figure 1i).
To test if the hyperpigmentation phenotype was due to an
activation of the MAP kinase pathway downstream of ras
signaling, we checked for ERK1/2 phosphorylation using Western
Blot analysis. An increase in the levels of phospho ERK was found
in kita-GFP-RAS larvae compared to controls (figure 1o).
Accordingly, treatment of kita-GFP-RAS larvae with UO126 (an
inhibitor of MEK1/2 and a copper chelator, [16] caused a
corresponding decrease of ERK1/2 phosphorylation (figure 1p)
and reduced hyperpigmentation to different degrees (figure 1m). In
contrast to UO126, treatment with PD98059 (which efficiently
inhibited ERK1/2 phosphorylation in kita-GFP-RAS larvae,
figure 1q) was unable to prevent hyperpigmentation (figure 1n).
This suggests that hyperpigmentation caused by melanocyte
hyperplasia in kita-GFP-RAS larvae is not due to ERK1/2
phosphorylation and is dependent on copper uptake (as in control
melanocytes [16]).
Kita-GFP-RAS fish develop melanoma at early stages, and
these tumors are similar to human melanoma
Zebrafish undergo a change in pigmentation pattern around 2–3
weeks of age. This period is known as metamorphosis and leads to the
mature pigment pattern of the adult fish, which is established around
4 weeks of age [17,18]. Kita-GFP-RAS fish develop an accumulation
ofmelanocytesatthelevelofthecaudalfinthatoftencausedisruption
of normal tissue surrounding these lesions that we call melanocytic
hyperplasia (figure s1) starting from 2 weeks post fertilization. These
lesions occur in almost 100% of double transgenics before
metamorphosis (melanocytic hyperplasia and in some cases juvenile
tumors, see figure s1e), but then not all of these lesions progress and
we could only find a black caudal fin after metamorphosis in several
kita-GFP-RAS transgenic fish at 1 month (figure s1) or 3 months
(figure 2b, e). Notably though in approximately 20% of 1–3 month
old kita-GFP-RAS fish (n=252), tumors progress to an invasive
phenotype (figure 2c, figure s1e, o). Most of these adult tumors are
hyper-pigmented, with a very low percentage of them (1–2%) being
hypo-pigmented (figure 2d).
In order to evaluate whether these tumors were invasive we
performed histological analysis on a collection of fish displaying
tumors. In figure 2f we show a fish displaying a tumor at the level
Figure 2. kita-GFP-RAS fish develop melanoma. a–d) Different phenotypes in three-month old kita-GFP-RAS zebrafish: a) control fish; b) black
caudal fin; c) large hyper-pigmented tumor; d) hypo-pigmented tumor. e) Percentage of the progeny of kita-GFP-RAS fish incross displaying a black
fin phenotype (BF) or tumor (T) at 3 months (mean6SD). f) Lateral view of a fish bearing an infiltrating melanoma of the mouth and head, which also
expresses mCherry (g) and GFP-RASV12 (h). H&E staining of parraffin sections of the fish in f) that display infiltrations of melanocytes in the head (i),
muscles (k), gills (j). Insets are from control animals. Calibration bars for i–j =100 mm.
doi:10.1371/journal.pone.0015170.g002
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Gal4-mCherry (figure 2g) and GFP-HRASV12 (figure 2h). We
observed that melanocytes were infiltrating various tissues/organs
including brain (figure 2i), muscles (figure 2k) and gills (figure 2j).
Histology performed on 2 week-, 4 week- and 2 month-old kita-
GFP-RAS fish showed progressive infiltration of tail tissue by
transformed melanocytes, (figure S2a, b) up to a complete
substitution of tail tissue with melanoma tissue (figure s2c).
Both hyper- and hypo-pigmented tumors are enriched in
melanocytes as revealed by EM analysis of tumor samples (figure
s2d, e) and in situ hybridization on cryostat section for dopachrome
tautomerase (dct, a marker of melanin biosynthetic pathway [19],
figure s2f).
To assess how useful this model could be to study the biology of
human melanoma progression we investigated the immunological
features of the zebrafish tumors using the same markers that are
used in diagnostic for human melanoma.
Immunostaining on zebrafish melanoma cryostat sections
including Tyrosinase [23], Melan-a [22], s100 [21] and HMB45
[6,20], revealed elevated expression of all these melanoma markers
showing that these tumors are immunologically similar to human
melanoma (figure 3).
We also performed an analysis of the proliferation, apoptosis
and presence of nuclear abnormalities in 5 different melanoma
samples and found that approximately 10% of melanoma cells are
dividing (figure 4a, b), whereas less than 1% of tumor cells undergo
nuclear fragmentation and show TUNEL labeling (figure 4c, d);
however, nuclear abnormalities were common in tumor cells and
dividing melanoblasts or binucleate melanocytes were found in
semithin sections of hyper-pigmented transgenic larvae (figure 4e)
and melanoma (figure 4f). Furthermore, we detected nuclear
abnormalities including multipolar spindles (figure 4g) and
polyploid nuclei (figure 4h) as commonly found in melanoma cell
lines.
Tumor formation does not require mutations in p53 or
PTEN
In two of the zebrafish melanoma models published so far [8]
[5] it has been shown that tumor formations occurs only in the
presence of inactivating mutations in tp53. To check whether
tumor formation in our model is also due to an intervening
mutation in tp53, we evaluated the ability of p53 to signal
transcriptionally following X-ray treatment of kita-GFP-RAS or
control fish by looking at the expression of two p53 downstream
targets, p21 and mdm2 [24]. Irradiation causes upregulation of
p53 targets and thereby we evaluated the levels of p21 and mdm2
expression in tumors deriving from kita-GFP-RAS irradiated fish.
The levels of p21 and mdm2 expression were found significantly
increased in quantitative PCR (figure 5a, b) indicating that p53 is
trascriptionally active in these tumors. We also grew kita-GFP-
RASV12 transgenic fish in a tp53-/- background [25]. We
observed that these fish had a much faster progression of
melanoma, requiring euthanasia at 1–3 months (not shown).
Irradiation of tp53-/- control fish did not cause any increase in the
levels of p21 and mdm2 expression. In tumors from kita-GFP-
RAS; tp53-/- zebrafish the levels of p21 and mdm2 expression, are
slightly increased after irradiation, suggesting that the residual
activation of p21 and mdm2 may be p53-independent (as reported
for other malignancies [26]). This suggests that tumor formation in
our model due to oncogenic HRAS takes place in the presence of
transcriptionally active p53. However, these results also suggest
that melanoma development is further enhanced by the lack of
p53 activity indicating a role for p53 as modulator of melanoma
formation in our genetic model.
It has been reported that in melanoma both the Ras/Raf/
MEK/ERK (MAPK) and the PI3K/AKT (AKT) signalling
pathways are constitutively activated through multiple mecha-
nisms [27,28]. In order to evaluate whether these pathways are
hyperactivated in our melanoma model we performed Western
Figure 3. Immunostaining of zebrafish melanoma cryostat sections. In the lower panels (a’–d’) immunostainings (magenta) for the markers
indicated in the lower right corners of each micrograph. All cells express GFP-RAS (green at the plasma membrane). Upper panels (a–d) show the DIC
image of each sample, which consisted mostly of unpigmented tumors. Calibration bars =50 mm.
doi:10.1371/journal.pone.0015170.g003
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fin and fin with tumors. We found a robust activation of the ERK
pathway (figure 5c, d) but we did not observe any increase of
phospho AKT (figure 5e) in spite of increased levels of total AKT
in tumors. Since there is an inverse correlation between PTEN
and AKT activation [29] we thought that AKT might be
indirectly dephosphorylated by PTEN with a very quick kinetic.
In order to test this hypothesis we checked the expression levels of
PTEN by Western blot analysis, and found elevated levels of
PTEN in tumor samples (figure 5e).
These results support the hypothesis that in our model, tumors
may develop in the presence of PTEN or p53 tumor suppressor
activities.
Melanoma development is dependent on mitfa
expression
We investigated whether the formation of melanoma in kita-
GFP-RAS transgenic fish relies on the expression of mitfa, the
master regulator of melanocyte survival and differentation [30].
We raised the kita-GFP-RAS line in a mitfa-/- background (a
mutant called nacre [31]) and observed that these embryos,
although initially expressing the GFP:HRASV12 transgene in
melanocyte progenitors (figure s3a) by 3 dpf were devoid of
melanocytes (figure s3b, e) and did not develop any tumor by 9
months of age. To further confirm that the expression of mitfa is
required for melanocyte survival and melanoma development in
double transgenic fish we mosaically re-expressed mitfa in kita-
GFP-RasV12/nacre embryos. To do so, we cloned the mitfa
coding region in a UAS expression vector (figure 6a) and injected
this construct in kita-GFP-RASV12/nacre embryos at one cell
stage. We observed already at 30hpf the presence of melanocytes
(figure 6b), able to proliferate and form clones (figure 6c), which
survived at least for a few weeks. This suggests that, as reported by
a large body of literature [30,32] mitfa expression is necessary for
melanocyte survival and the expression of HRASV12 is not
sufficient to rescue them.
We then used transplantation in nacre fish to investigate if the
oncogene activity is cell-autonomous and whether its expression
confers melanocytes the ability to survive and positively compete
with host cells. To do so we transplanted cells from kita-GFP-RAS
(donor) into nacre or wild type (AB) embryos (host) at blastula
(figure 6d, e). We raised all the transplanted fish and we observed
that 57% of nacre fish receiving cells from kita-GFP-RAS donors
developed tumors associated with a black caudal fin phenotype
(figure 6e). In AB hosts, donor kita-GFP-RAS cells survived and
proliferate to generate melanocytic hyperplasia in a similar
percentage of cases (49%). This result suggests that kita-GFP-
RAS cells maintain their transformed and aggressive phenotype in
a completely cell-autonomous fashion, and that ras-expressing
melanocytes survive and thrive equally well in the presence or in
the absence of competition from host melanocytes. Thus, a large
percentage of kita-GFP-RAS expressing cells is able to initiate
melanoma development in a host environment.
Expression of HRASV12 under the mitfa promoter does
not reproduce the kita-GFP-RAS phenotype
Altogether, these results suggest that targeting the expression of
the HRAS oncogene to a population of cells that express the kita
gene is able to induce melanoma development with high efficiency
(i.e. without the need for additional mutations that inactivate
Figure 4. Histology of kita-GFP-Ras melanoma. a) BrdU+ nuclei (magenta) in a section of a melanoma developing in a 3-month-old kita-GFP-
RAS fish. b) Diagram showing percentage of BrdU+ cells in control skin (C) and melanoma (T) sections (n=5). c) TUNEL+ nuclei (red) in a cryostat
section of a melanoma developing in a 3-month-old kita-GFP-RAS fish. d) Diagram showing percentage of TUNEL+ cells in control skin (C) and
melanoma (T) sections (n=5). e) Semithin (0.5 mm thick) resin section of a 5dpf kita-GFP-RAS larva, showing several melanocytes, one of which is at
the end of mitosis. Arrows point to the two chromosomal condensations. f) Semithin section of a tumor from a 3-month-old kita-GFP-RAS fish
showing enrichment in melanocytes one of which is binucleate (arrows). g–h) Cryostat sections of melanomas developing in kita-GFP-RAS 3-month-
old fish. All cells express GFP-RAS (green at the plasma membrane) and have DAPI (blue) counterstained nuclei. Arrows point to a multipolar spindle
(g) and a polyploid giant nucleus with condensed chromosomes (h). Calibration bars: 50 mm.
doi:10.1371/journal.pone.0015170.g004
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hypothesize that the aggressive features of our model depends not
so much on the oncogene which has been used also in another
zebrafish model of melanoma [6], but rather on the cell types that
are targeted by the kita promoter perhaps also in conjunction with
higher levels of oncogene expression.
We tested the ability of the UAS:HRASV12 transgene to induce
melanoma development following expression in somatic cells (i.e.
in F0, after injection of the UAS:GFP-HRASV12 plasmid in the
tg(mitfa:Gal4VP16; UAS:mCherry) line - named mitfa:Gal4 to
simplify, or in the kita:Gal4 line, figure 7a). This approach is
commonly thought to yield high level of expression. Here we
evaluated abnormal melanocyte proliferation at 4dpf (figure 7c, f),
15dpf (figure 7d, g) and transformation at 1 month (figure 7e, h) in
larvae/juveniles that were selected for 1 or more transient
integration events (i.e. displaying GFP+ cells) at 2 dpf. At 4 dpf
lesions in both lines (n=132 in mitfa:Gal4 and n=110 in
kita:Gal4) were composed of several melanocytes, indicating that
the oncogene stimulates proliferation and supported the clonal
expansion of the cell carrying somatic insertion of the oncogene
(figure 7c, f). At 15 dpf 57.3% of the melanocytic lesions in the
Et(kita:GalTA4,UAS:mCherry)hzm1 (39 out of 68 survivors) were still
expanding (figure 7b, d), whereas only 17.2% were detectable in
the mitfa:Gal4-mCherry line (16 out of 93 survivors, figure 7b, g).
At 1 month 50% of the kita:Gal4-mcherry HRASV12 injected fish
showed clear malignant melanoma (22 out of 44 survivors,
figure 7b, e), whereas melanomas were present in only 11% of the
mitfa:Gal4-mcherry HRASV12 injected fish (9 out of 83 survivors,
figure 7b, h), indicating that many melanocytic lesions present at
15 dpf had regressed. We also compared melanoma development
in double transgenic lines obtained from mitfa:Gal4 or kita:Gal4
crossed to the same UAS:GFP-HRASV12 reporter line. The ras
oncogene was expressed in a similar pattern in migrating neural
crest cells in both mitfa-GFP-RAS and kita-GFP-RAS double
transgenic embryos at 30 hpf (but in fewer cells in the mitfa-GFP-
RAS line figure s4a, b), but the hyper-pigmentation phenotype
does not develop in the mitfa:GFP-RAS larvae (figure s4c). We
observed tail melanocytic hyperplasia in 3 out of 25 double mitfa-
GFP-RAS transgenics at 24 dpf (which regressed completely by 34
dpf) and one case of a head melanoma at 3 month of age (in 25
double transgenic adult fish, figure s4d).
To understand the reasons of the difference between mitfa and
kita driver lines in developing melanoma, we studied the cell types
that express the oncogene under the control of the two driver lines.
We found that in kita-GFP-RAS embryos and larvae other cell
types not previously associated with the melanocytic lineage
express the oncogene. None of these cell types display features of
melanoblasts (being mostly terminally differentiated cells, see
figure s4g, h). However, there is a possibility that these cell types
share the same lineage of melanocytes and that the kita-GFP line
may provide insights on this. We then investigated if the
differences between the two driver lines are due to different level
of HRAS being expressed or maintained in melanocytes using
western blot analysis, and found that in the mitfa-GFP-RAS line
the levels of RAS expression are very low compared with those
found in kita-GFP-RAS larvae and adults (fig. s4i). This result
suggest that the higher penetrance and earlier onset of melanoma
in the kita-GFP-RAS line versus mitfa-GFP-RAS line could be due
Figure 5. kita-GFP-Ras tumors have a robust p53 pathway activation. a–b) QPCR analysis of tp53 target gene expression. p21(a) and mdm2
(b) mRNA expression in control (C) or tumors from kita-GFP-RAS transgenic fish (T) with a wild-type (tp53+) or mutant (tp53 -) background genotype,
as indicated. Samples were subjected to X-ray irradiation (IRR +) or left unirradiated (IRR -). All data are expressed as Mean Normalized Expression and
were normalized to the expression levels of b-actin as an endogenous control. Error bars indicate s.d. except for tp53-/-, for which the error bars
indicate range. n=3 for C tp53+, IRR-; n=3 for C tp53+, IRR+; n=9 for T tp53+, IRR-; n=3 for tp53+, IRR+; n=2 for C tp53- IRR-; n=2 for C tp53- IRR+;
n=1 for T tp53- IRR-; n=1 for T tp53- IRR+. c-e) RAS pathway activation in tumor. c) Protein extracts from control and fin with tumor show active ras
(Ras-GTP, immunoprecipitated with Raf1). Western Blot analysis of protein extracts prepared from control (C), fin with tumor (T) and black fin (BF)
show an increased phosphorylation of ERK1/2 (d) and increased amounts of total AKT, but not phospho-AKT, which correlates with an increase in
PTEN levels (e).
doi:10.1371/journal.pone.0015170.g005
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different cell specificity of the two promoters.
Discussion
Here we report on a genetic, inheritable zebrafish model of
melanoma, which has a number of properties providing insights
and tools for the study of melanoma biology and that shows
features comparable to human melanoma.
First, this model shows that expression of oncogenic HRAS can
initiate and maintain melanoma formation without the need for
inactivating mutations in tumor suppressors as reported for other
(zebrafish and mouse) models of melanoma [8,33]. Second, the
presence of a larval phenotype that is a direct precursor of the
melanoma lesions that develop at later stages, allows rapid, easy to
score and specific chemical screens aimed at finding compounds
and drugs that may revert the hyper-pigmentation phenotype.
Third, the model provides a rapid approach to gene manipulation
specifically in the HRAS transformed cells, that could be exploited
for large scale suppressor (and enhancer) screens, through the use
of UAS elements to drive expression of cDNA libraries, or for
validation of drug target candidates. Fourth, the model allows to
image cancer cells in vivo thanks to the expression of GFP.
Genetic melanoma models which reproduce the human
phenotype and provides a source of stageable cancer samples
are strongly needed to test hypotheses on the mechanisms of
malignant transformation, identify melanoma initiating cells and
study their features in order to devise way of eradicating them.
The presence of well-defined intermediate stages of cancer
development will provide the blueprint for marker/signature
analysis of transcriptome, epigenome and proteome [34]. Even
more ideal would be a flexible model suitable for genetic
manipulation, in vivo imaging and pharmacogenomic approaches.
Our model is amenable to all these approaches and in the
following paragraphs we will briefly discuss the main findings
obtained with this versatile melanoma model.
Larval hyperpigmentation is an early sign of melanoma
development and can be used in pharmacological
screens aimed at finding anti-melanoma drugs
One of the features of our model is the development of a
hyper-pigmentation phenotype at early larval stages which is
suitable for large scale chemical screens aimed at discovering
drugs that controls melanocyte number, migration and trans-
formation. One important question here is whether larval
hyperpigmentation in our model is associated with melanoma
development. Hyperpigmentation has been reported in larvae
overexpressing kit ligand (kitL,[35]. The hyperpigmentation
phenotype due to overexpression of kitL resemble a human
condition known as Familial Progressive Hyperpigmentation
(FPH, MIM #145250) which is also due to gain of function
mutations in KIT ligand [36] and has not been associated with
melanoma development. From these data it appears that c-kit
signaling controls proliferation, size and migration of melano-
blasts and melanocytes. However an increase of kit signaling is
not per se able to induce transformation of these cells and to
sustain melanoma development [36–37]. Conversely, congenital
nevi in children frequently harbor RAS, but not BRAF
mutations [38] and are associated with an increasing risk of
melanoma development. In our model the expression of
oncogenic ras in larval melanocytes or their precursors is able
to induce them to proliferate, subvert their interactions with
neighbouring cells promoting multilayer growth, causes changes
in shape and migration, induces polyploidy and alter their
normal development. Both somatic and germline expression of
HRASV12 in kita+ cells can induce melanoma development
from larval stages. This observation suggests that there is a
continuum between transformed larval melanocytes and various
grades of melanocytic lesions up to melanoma, which makes the
larval hyperpigmentation phenotype a truly pre-melanoma
phenotype. The parallels between congenital RAS-induced nevi
and the clusters of transformed melanocytes in transgenic larvae
suggest that the kita-GFP-RAS line could be a useful model for
this condition.
Unique advantages of the kita-GFP-RAS melanoma
model
The zebrafish melanoma model described here has unique
advantages over other zebrafish and mouse models of melanoma.
First, the expression of a GFP tagged oncogene in melanoblasts
Figure 6. Melanoma development is dependent on mitfa
expression. a) Schematic diagram of the construct and injection
strategy used to re-express mitfa in mitfa-/- (nacre); kita-GFP-RAS
zebrafish. Transformed melanocytes in the head of a 30hpf (b) and in
the trunk of 5dpf (c) mitfa-/- (nacre); kita-GFP-RAS injected larvae. d)
Schematic representation of the transplantion strategy, where cells
were transplanted from kita-GFP-RAS embryos into mitfa-/- (nacre)
embryos at approximately 1000 cell stage. e) Picture of 4 month-old
trasplanted mitfa-/- (nacre) fish displaying a patchy recovered pigment
pattern and a small tumor at the level of the caudal fin (arrow).
Calibration bars=100 mm for b,c; 2 mm for e.
doi:10.1371/journal.pone.0015170.g006
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the earliest stages of transformation. This is a great potential of the
model making it accessible for non-invasively tracing of trans-
formed melanocytes. Other aspects that can be studied in vivo using
this model are the ability of ras transformed cells to escape
immune-surveillance [39] or to induce favorable changes in the
microenvironment that could promote the survival and expansion
of clones of melanoma cells.
A second advantage of the melanoma line described here is the
possibility of manipulating gene expression specifically in the
transformed cells, thanks to the use of UAS elements to drive the
expression of genes in the same cells that express oncogenic ras.
The problem of melanoma initiating cells and the role of
inactivating mutations in tumor suppressors
One of the most debated concepts in cancer research is the
ability of oncogenes to transform. Decades of studies have revealed
that not all cells respond to oncogenes by generating cancer. Very
efficient tumor suppressor mechanisms exist that control the cell
response to oncogenes, making them harmless, and these include
apoptosis and cellular senescence (reviewed in [40]).
This is why most tumors develop only following two causative
hits: firstly a mutation that transform a cellular gene in an
oncogene, and secondly, a mutation that inactivate a tumor
suppressor [41]. The need for the occurrence of two mutations
may be bypassed by different mechanisms: on one side levels and
activity of the oncogene may be so high, and the oncogene may be
expressed in many cells (as in genetic cancer predisposition
syndromes due to germline mutations) that neither apoptosis nor
cellular senescence can get rid of all the transformed cells. Another
mechanisms could be intrinsic to the cell type where the activating
mutation takes place.
A growing body of evidence (reviewed in [42]) suggests that
tumor suppressors are less active in stem/progenitor cells, as their
activity would eliminate a multipotent progenitor, with very
disruptive consequences for the whole organism. Mutations that
inactivate tumor suppressors may be seen as absolutely necessary
in the oncogenic transformation of terminally differentiated cells,
while they may not be necessary to induce transformation in a
multipotent progenitor, where tumor suppressors are less active.
In this study we have shown that kita expressing melanoblasts
can be efficiently transformed by the HRAS oncogene in the
presence of active p53 and give rise to melanoma with a higher
efficiency and much lower latency than mitfa expressing melano-
blasts and melanocytes. This difference may be due to the higher
levels of HRASV12 expression driven by the kita and/or to
different cell specificity of the kita and mitfa promoters. We have
also observed the development of tail melanocytic hyperplasia in
the majority of ras expressing metamorphic larvae suggesting that
kita-expressing melanoblast progenitors may concentrate/reside in
Figure 7. Comparison between mitfa and kita Gal4 driver lines. a) Schematic diagram of the construct and injection strategy used to
transiently express GFP-HRASV12 in the mitfa:Gal4 and kita:Gal4 lines. b) Percentage of injected fish that display melanoytic hyperplasia/melanoma
(MH) at 2 and 4 weeks (w) post fertilization. c–e) 4, 14 and 32dpf kita-Gal4 fish injected with UAS-GFP-HRASV12 plasmid for somatic integration.
Mosaic expression of the transgene leads to abnormal melanocytes (c), persistent melanocytic hyperplasia (d) and melanoma (e) f–h) 4, 14 and 32dpf
mitfa-Gal4 fish injected with UAS-GFP-HRASV12 plasmid. Mosaic expression of the transgene in this driver line generates fewer and smaller
melanocytic lesions. Calibration bars =2 mm.
doi:10.1371/journal.pone.0015170.g007
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development. While this location seems to be specific for the fish,
the occurrence of certain types of melanoma in humans in
preferential locations (acral and mucosal melanoma, reviewed in
[43]) may suggest a similar developmental mechanism (i.e.
residence of melanoblast stem cells) that would be worth
investigating.
In conclusion, we have reported here on a new model of
melanoma in zebrafish, which provides new tools and new insights
for the study of the biology of melanoma cells. It also holds the
promise that the similarities between fish and human melanoma
go beyond anatomical and developmental specificities, thus
facilitating the use of this genetic model for human disease study
and treatment.
Methods
Zebrafish strains and maintenance
Adult zebrafish (Danio rerio) were maintained as described
[44]. Strains included: AB; tg(UAS:GFP) (a kind gift of Masa
Tada, UCL), tg(5XUAS:eGFP-HRASV12)io6 [14], mitfa
w2/w2 [31],
p53
zdf1/zdf1 [25] and tg(mitfa:Gal4VP16;UAS:mCherry);E t ( kita:Gal-
TA4,UAS:mCherry)hzm1[13]. The double transgenic line Et(kita:-
GalTA4,UAS:mCherry)hzm1xtg(UAS:eGFP-H-RASV12)io6 was also
raised in tp53-/- background [25]. Work with zebrafish was
carried out under EU regulations for animal experimentation.
The project was approved by Ministero della Salute - Direzione
Generale della Sanita ` Animale e Del Farmaco Veterinario-
Ufficio VIu, protocol number 02/2010 (under decree 116/92).
Generation of driver and reporter lines
The tg(UAS:eGFP-HRAS_G12V)io6 line was generated as de-
scribed (19). For the generation of tg(mitfa:Gal4VP16, UAS:mCherry)
line the mitfa:Gal4VP16, UAS:mCherry transgene was constructed by
inserting a mitfa proximal promoter fragment [6] before a
Gal4VP16-15XUAS tandem self-reporting fragment (a kind gift of
Michael Parsons), itself placed before intron 1 of the zebrafish
EF1alpha gene combined with mCherry cDNA. The plasmid
backbone was pT2AL200R150G (a kind gift from Koichi
Kawakami). The construct was injected into 1-cell stage zebrafish
embryos and a transgenic line with neural crest restricted expres-
sion expanded.
Live imaging of transgenic zebrafish
Anaesthetised transgenic larvae were embedded in 1% agar and
viewed with a Leica SP2 confocal microscope.
Melanocyte quantitation
Embryos were raised in different light regimes from birth till
3dpf. They were fixed in 4% paraformaldehyde overnight, and
then transferred into phosphate-buffered saline containing 10%
Tween-20. Pigment cells in the dorsal pigment stripe on the
anterior of the embryos were imaged using a up-right microscope
(Nikon,Tokio Japan). We manually counted the number of
melanocytes in the region of interest using the NIS-elements
software (Nikon).
For epinephrine treatment (to cause contraction of melanocytes)
embryos were exposed to epinephrine (Sigma) 1 mg/ml for 10
minutes and then fixed in cold 4% paraformaldehyde.
BrdU labeling and TUNEL assay
For BrdU labeling, we incubated 72hpf larvae or adult fish in
10 mM BrdU in E3 fish water for 12 hours. Following fixation in
4% paraformaldehyde, larvae were treated with 2N HCL for 20
minutes, before processing them for immunofluorescence with
anti-BrdU antibody (Sigma). A Cy5 conjugated secondary
antibody was used to reveal BrdU uptake. For the adult fish,
tumors or corresponding healty skin from control fish was excised
after a light fixation and maintained in 4% paraformaldehyde
overnight, before equilibration in 25% sucrose in phosphate
buffered saline (PBS) and embedding in OCT. Cryostat sections
(12 mm thick) were treated with 2N HCL as above and processed
for immunohistochemistry as described for whole mount larvae.
Apoptotic cells in larvae or adult fish were specifically detected
by ApopTag Red In Situ Apoptosis detection kit (S7165,
Chemicon), which is based on terminal transferase dUTP nick-
end labelling (TUNEL) assay. Samples were mounted in
Vectashield (Vector Laboratories, Inc.) with DAPI.
Percentages of BrdU and TUNEL labelled melanocytes were
evaluated in 6 controls (kita-GFP) and 6 kita-GFP-RAS larvae at 4
dpf after overnight exposure to BrdU. At least 200 melanocytes
per speciments were evaluated for BrdU labelling. For tumor
sections, counts refer to an area of 2.4 mm
2. At least 3 sections,
from 6 different tumors were analyzed.
Immunofluorescence and antisera
Adult fish were killed by anesthetic overdose and tumors or
corresponding areas from wild-type fish were excised and
embedded unfixed in optimum cutting temperature (OCT; Sakura
Finetek, Torrance, CA). Cryostat sections (14 mm thick) were fixed
in 2% paraformaldehyde for 2 min. We used the following
antisera: anti HMB 45 (1:50 Novo Castra laboratories), and s100
(1:50 Novo Castra laboratories), Melan-A (Novo Castra laborato-
ries), and Tyrosinase (H-109) (1:50 SantaCruz). Secondary
antibodies conjugated with Alexa633 were from Molecular Probes
(Carlsbad, CA). 49,6-Diamidino-2-phenylindole (DAPI) counter-
stain was carried out on all sections. The expression of
HRASGV12-GFP was still visible as green fluorescence.
Western Blot analysis and Ras activation assay
Adult fish were killed by anesthetic overdose (0,04% MESAB,
Sigma), the tumors were homogenized in sample buffer (2%
SDS, 10% glycerol, 60 mM Tris pH 6.8). 20–50 mgo ft o t a l
extracts were resolved by SDS-PAGE, transferred to nitrocellu-
lose and tested with the following antibodies: RAS (1:500, BD
bioscience), Phospho-p44/42 (1:1000, Cell Signaling), p44/42
(1:1000, Cell Signaling), Phospho-AKT (1:1000, Cell Signaling),
AKT (1:1000, Cell Signaling), PTEN (1:1000, Cell Signaling),
Actin (MP Biomedical). We performed the StressXpress Ras
Activation kit (Stressgen, Bioreagents) on protein extracts from
larvae and juvenile fish according to the manufacturer’s
instructions.
Drug treatment
Embryos starting from shield stage were incubated in Petri
dishes with diluted compounds: 1 mg/ml of PD98059 (Calbio-
chem) or 10 mM of U0126 (Calbiochem) with 0.2% DMSO in E3
medium [45]. Embryos were kept in the dark to protect drugs
from degradation.
Histology and electron microscopy
Paraffin Embedding and H&E staining: the fish were dehy-
drated in alcohol, decalcificated in 0.25M EDTA, cleared in xilene
and infiltrated with paraffin. Briefly slides were deparaffinized in
xilene, passed throught graded alcohols, rinsed in water and briefly
soaked in Hematoxylin and then in Eosin. Slides were dehydrated
and mounted using EUKITT (GmbH & Co).
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paraformaldehyde and 2% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4) over night, and postfixed in 1% osmium tetroxide
for 1 hour. The specimens were then rinsed in buffer, dehydrated
in a graded ethanol series and embedded in Epon. Semithin
sections (1 mm) were stained with Methylene Blue for light-
microscopic analysis. Thin sections (around 60 nm) were stained
with uranyl acetate and lead citrate, then viewed by TEM (Philips
CM100).
RNA extraction and Quantitative PCR
Five month old wt and Et(kita:GalTA4,UAS:mCherry)hzm1;Tg(UA-
S:eGFP-H-RASV12)io6 also in the tp53-/- background (also with
tumor) were gamma irradiated or not with 12 Gy (Santoriello et al.,
2009). After 16 hrs caudal fins were collected and omogenized in
RLT buffer, and total RNA was extracted with RNeasy mini kit
(Quiagen). After treatement with turbo DNAse (Ambion), RNA
quantity was determined by spectrophotometer. cDNA was synthe-
tized from total RNA (100 ng) using SuperScript VILO (Invitrogen)
according to the manufacturer’s instructions. Quantitative Real-time
PCR was performed with LightCyclerH 480 II thermocycler (Roche)
using the SYBR Green I Master kit (Roche). cDNA (1 mlo n2 0ml)
was amplified in triplicate in a reaction volume of 25 ml. Primers,
designed using Primer 3, were: p21 forward: 59-ATGCAGCTCCA-
GACAGATGA-39, p21 reverse: 59-CGCAAACAGACCAACAT-
CAC-39,m d m 2f o r w a r d :5 9-CCGAGGCAGACTACTGGAAG-39,
mdm2 reverse: 59-GGAAGGTTGTGTTGGGAGTT-39, b-actin
forward: 59- CGAGCAGGAGATGGGAACC-39, b-actin reverse:
59- CAACGGAAACGCTCATTGC-39. The conditions for the
reactionswerethefollowing:10 minat 95uC, followed by 40 cycles of
15 s at 95uCa n d6 0sa t6 0 uC. For any sample the expression level
was analyzed using Q-GeneH s o f t w a r e ,w h i c he x p r e s s e sd a t aa sm e a n
normalized expression. All the genes were normalized to expression
of b-actin as an endogenous control.
Transplants and mosaic analysis
Genetic mosaics were generated by transplantation following
standard protocols [45]. Donor kita-GFP-RasV12 embryos were
allowed to develop until shield stage. Approximately 20–30 cells
were then transplanted into age-matched nacre host embryos.
Embryos were raised to adulthood and checked for tumor
formation.
For the re-expression of mitfa into nacre-GFP-RAS line we
injected a T2MUAMCS plasmid containing the mitfa cDNA in
combination with Tol2 transposase.
For somatic expression, the UAS-eGFP-RasV12 plasmid was
injected in combination with the transposase (25nl plasmid+35nl
transposase mRNA) at one cell stage into the kita:Gal4 and
mitfa:Gal4 embryos [46]. Larvae were sorted for eGFP-RasV12
expression. We counted the number of fish displaying melanocytic
lesions at 4dpf, 15dpf and 1month.
Supporting Information
Figure S1 Range of caudal fin phenotypes in kita-GFP-
RAS juvenile fish. a, f, k) control fish (kita-GFP line). b–e, g–j, l–
o) kita-GFP-RAS line. a–e) 15 dpf; f–k)18–22 dpf (pre-metamor-
phosis); j–o) 21–28 dpf (postmetamorphosis). Tumors are present
in e, j, o. Calibration bar =1mm
(TIF)
Figure S2 Histology of melanoma. a–c) H&E staining of
representative tail regions of kita-GFP-RAS fish at the ages
indicated. d–e) Representative electromicrographs of a hyperpig-
mented (d) and a hypopigmented (e) melanoma. f) in situ hybridization
for dopachromo tautomerasis (dct) in a cryostat section of a tail
hypopigmented melanomafrom a1 month oldtransgeniczebrafish.
Calibration bars =100 mm for a,b,c,f; 0.5 mm for d and e.
(TIF)
Figure S3 Expression of kita-HRASV12 in mitfa-/-
(nacre) background is unable to rescue melanocyte
survival. a) Migratory neural crest are the only cells expressing
GFP-HRAS in 3 dpf kita-GFP-RAS embryos in a nacre background
(b). Compare with fully differentiated, transformed tail melano-
cytes (c) in a 3 dpf kita-GFP-RAS embryo in a AB background (d).
e) 21 dpf nacre x kita-GFP-RAS fish is devoid of melanocytes, as
opposed to AB x kita-GFP-RAS fish (f), which has increased
pigmentation. Calibration bar 100 mm for a–d; 2 mm for e–f.
(TIF)
Figure S4 Similarities and differences between mitfa-
GFP-RAS and kita-GFP-RAS transgenic lines. a–b, e–f)
Similar expression pattern, but different number of GFP-RAS
migrating melanocyte progenitors at 32 hpf in mitfa-GFP (a,b) and
kita-GFP (e,f) double transgenic zebrafish. c) Normal pigmentation
in a 5 dpf mitfa-GFP-RAS larva. d) The only melanoma that
developed in mitfa-GFP-RAS fish by three months of age (n=25).
g–h) Other cell types expressing GFP under the kita promoter.
Melanocytes and mucous cells (arrows) in kita-GFP 3dpf larvae (g).
Flat epithelial cells (enlarged in inset), present in the fins of kita-GFP
3 dpf larvae (k). These cells do not change in number or size upon
expression of HRAS. i). Western Blot analysis of protein extracts
from double transgenic fish at the age indicated in the upper lane.
Increased levelsof Rasin kita:GFP-RASversus mita:GFP-RASfish.
Calibration bars: 50 mm in a–b;e–n; 2 mm in c–d.
(TIF)
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